Oaktree Capital Management »

Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Oaktree Capital Management

Quarter-by-quarter ownership of Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Oaktree Capital Management from 13F filings

Historical chart of Oaktree Capital Management investment in Sarepta Therapeutics Inc Note 1.250 9/1

Tip: Access up to 7 years of quarterly data

All positions including Sarepta Therapeutics Inc Note 1.250 9/1 held by Oaktree Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sarepta Therapeutics Inc Note 1.250 9/1 by Oaktree Capital Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $31M 35M 0.88
2025-06-30 $3.6M 4.9M 0.72
2025-03-31 $9.4M 10M 0.93
2024-12-31 $9.7M 8.8M 1.10
2024-09-30 $7.4M 6.5M 1.14
2024-03-31 $2.3M 2.0M 1.17
2023-12-31 $2.0M 2.0M 1.02
2023-09-30 $2.2M 2.0M 1.12

More positions owned by Oaktree Capital Management

Torm Common Stock (TRMD)
Expand Energy Corp Common Stock (EXE)
Garrett Motion Common Stock (GTX)
Anglogold Ashanti Common Stock (AU)
Viper Energy Common Stock (VNOM)
State Street Corp Etf Put Option (SPY)
Talen Energy Corp Common Stock Call Option (TLN)
Telephone And Data Systems Common Stock (TDS)
Oracle Corp Common Stock Put Option (ORCL)
Sunopta Common Stock (STKL)
Core Scientific Common Stock (CORZ)
Barrick Mining Corp Common Stock (B)
Liberty Global Common Stock (LBTYA)
Ftai Aviation Common Stock (FTAI)
Cemex Sab De Cv Common Stock (CX)

View all positions for Oaktree Capital Management

Top funds holding Sarepta Therapeutics Inc Note 1.250 9/1

Balyasny Asset Management
Linden Advisors
Highbridge Capital Management
Oaktree Capital Management
D. E. Shaw & Co
DG Capital Management
Calamos Advisors
Davidson Kempner Capital Management
Agf Management
Readystate Asset Management
LMR Partners
State Street Corporation
Silver Point Capital
Man Group
Capstone Investment Advisors

View all funds holding Sarepta Therapeutics Inc Note 1.250 9/1